N@N

VICL, LMNX, ILMN, SFM, PCMI, SAGE, Expected to Trade Lower After Bearish Insider Trading

^{Published on 2017-01-17 04:45:04 - WOPRAI}
 

January 17, 2017 / M2 PRESSWIRE / BUYINS.NET / http://www.squeezetrigger.com is monitoring top insider trading patterns and these stocks are the most likely to trade Lower in the next 6 months. Vical Incorporated (NASDAQ:VICL), Luminex Corporation (NASDAQ:LMNX), Illumina, Inc. (NASDAQ:ILMN), Sprouts Farmers Market Inc. (NASDAQ:SFM), PCM Inc. (NASDAQ:PCMI), Sage Therapeutics (NASDAQ:SAGE) are all expected to go Lower as Sell signals have been generated by top insider trading patterns. The most important data elements considered when performing insider analysis are: Insiders Track Record - An insiders track record is best summarized by the Insider Score which ranges from 1 (least predictive) to 100 (most predictive) based on prior trading performance. In addition, the actual returns following the insiders prior trades are included to determine the potential magnitude of future returns. Insiders Role - Trades by higher-level insiders are generally more predictive than trades by lower level insiders. Higher-level insiders to include Chairman (CB), Chief Executive Officer (CEO), President (P), Chief Financial Officer (CFO), and Vice Chairman (VC).

The chart below displays the stocks expected to go Lower along with the insider name, position, predictive insider score, 6 month expected return and number of trading decisions included in the score.

  Symbol  Company Name                     Insider Name                     Role     Shares      Insider Score  Avg 6 Month Return  # of Dec. 
  VICL    Vical Incorporated               Smith, Lawrence Russell          O        54          99             -20.4%              11        
  LMNX    Luminex Corporation              Loewenbaum, George Walter        D        20,000      80             -8.3%               29        
  ILMN    Illumina, Inc.                   Dadswell, Charles E              GC       116         86             -3.1%               20        
  SFM     Sprouts Farmers Market Inc.      Sanders, James Douglas           D        45,000      96             -23.1%              11        
  PCMI    PCM Inc.                         Khulusi, Frank F                 CEO      80,150      97             -60.9%              14        
  SAGE    Sage Therapeutics                Iguchi, Kimi                     CFO      10,000      86             -25.1%              5         

Vical Incorporated (NASDAQ:VICL) - Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Its product candidates include CyMVectin prophylactic vaccine for cytomegalovirus (CMV), which completed preclinical trial to prevent infection before pregnancy to preclude fetal transmission; therapeutic vaccine and prophylactic for herpes simplex virus type 2, which is under Phase 1/2 clinical trial to prevent and protect against recurring flare-ups, reduce viral shedding, and transmission; and VL-2397 antifungal, which is in Phase 1, for the treatment of fungal infections. The company, through corporate collaborations, is also developing ASP0113, which is under Phase III clinical trial for prevention of CMV reactivation in stem cell transplant recipients, as well as in Phase II clinical trial for prevention of CMV infection in kidney transplant recipients; and ONCEPT therapeutic cancer vaccine encoding human tyrosinase for the treatment to enhance survival time of dogs with oral melanoma. In addition, it engages in contract manufacturing of plasmid investigational products for various clients. The company was founded in 1987 and is headquartered in San Diego, California..

Luminex Corporation (NASDAQ:LMNX) - Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and life sciences industries worldwide. It develops proprietary instruments and assays utilizing its xMAP open-architecture multi-analyte platform, MultiCode real-time polymerase chain reaction (PCR), and multiplex PCR-based technologies. The company s products include Luminex LX 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; and ARIES system, a sample to answer real-time PCR platform. It also offers MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; ARIES cassettes that are self-contained assay consumables; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; respiratory viral family of products to identify the causative agent for respiratory infections; and gastrointestinal pathogen panel assays to identify the pathogens causing infectious gastroenteritis. In addition, the company offers MultiCode assays and products comprising HSV 1&2 assays, analyte specific reagents, and other products to detect infectious agents in clinical samples; ARIES HSV 1&2 assays; cystic fibrosis family of products comprising IVD kits for cystic fibrosis genotyping; pharmacogenetics family of products consisting of assays to determine the drug metabolism status; and specialty product family and instrumentation products, as well as operates as an original equipment manufacturer of custom reagents and instrumentation. It serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is headquartered in Austin, Texas..

Illumina, Inc. (NASDAQ:ILMN) - Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company s sequencing by synthesis technology provides researchers with various applications and the ability to sequence mammalian genomes. It also offers arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow for the detection of known genetic markers on a single array. In addition, the company provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and non-invasive prenatal testing services. It serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as through life-science distributors. It has collaboration agreements with MolecularMD Corporation for drug-diagnostic co-development with biopharma drug programs; IBM Watson Health to access genome data interpretation by integrating Watson for genomics into Illumina s BaseSpace Sequence Hub and tumor sequencing process; and NRGene to develop new molecular breeding tools for cattle to support global food production. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California..

Sprouts Farmers Market Inc. (NASDAQ:SFM) - M/L STRIDES CITICORP.

PCM Inc. (NASDAQ:PCMI) - PACIFIC MARINE INDS.

Sage Therapeutics (NASDAQ:SAGE) - Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. The company s lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE). It is also conducting an additional Phase II exploratory trial of SAGE-547 in the treatment of severe post-partum depression (PPD). In addition, its pipeline includes next-generation product candidates, such as SAGE-217, a novel neuroactive steroid, which is in Phase I clinical trial for the treatment of orphan epilepsies and essential tremor, as well as for PPD; and SAGE-689, an acute adjunctive IV therapy for the treatment of indications where a high degree of anti-seizure activity and sedation are desirable prior to the introduction of general anesthesia. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts..

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS Friction Factor - Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements" Naked Shorts (RegSho) - Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING Earnings - Predicts probability, price move and length of move before and after all US stock earnings reports Seasonality - Predicts probability, price move and length of move based on exact time of year for all US stocks Group Correlation - Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups SqueezeTrigger - Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock. Valuation - Tracks all known valuation models and applies them. GATS - Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies. PatternScan - Automates tracking of every technical pattern and predicts next move in stocks. Insider - Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders Events - Tracks patterns directly correlated to specific events.

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net